Relaxin activates AMPK-AKT signaling and increases glucose uptake by cultured cardiomyocytes
Purpose Many evidences show that the hormone relaxin plays a pivotal role in the physiology and pathology of the cardiovascular system. This pleiotropic hormone exerts regulatory functions through specific receptors in cardiovascular tissues: in experimental animal models it was shown to induce coro...
Gespeichert in:
Veröffentlicht in: | Endocrine 2018-04, Vol.60 (1), p.103-111 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 111 |
---|---|
container_issue | 1 |
container_start_page | 103 |
container_title | Endocrine |
container_volume | 60 |
creator | Aragón-Herrera, A. Feijóo-Bandín, S. Rodríguez-Penas, D. Roselló-Lletí, E. Portolés, M. Rivera, M. Bigazzi, M. Bani, D. Gualillo, O. González-Juanatey, J. R. Lago, F. |
description | Purpose
Many evidences show that the hormone relaxin plays a pivotal role in the physiology and pathology of the cardiovascular system. This pleiotropic hormone exerts regulatory functions through specific receptors in cardiovascular tissues: in experimental animal models it was shown to induce coronary vasodilation, prevent cardiac damage induced by ischemia/reperfusion and revert cardiac hypertrophy and fibrosis. A tight relationship between this hormone and important metabolic pathways has been suggested, but it is at present unknown if relaxin could regulate cardiac metabolism. Our aim was to study the possible effects of relaxin on cardiomyocyte metabolism.
Methods
Neonatal rat cardiomyocytes were treated with relaxin and (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assays (MTT) were performed to assess metabolic activity; while 2-deoxy-D-[
3
H] glucose and BODIPY-labelled fatty acid incorporations were analyzed to measure glucose and fatty acid uptakes, and western blot was utilized to study the intracellular signaling pathways activated by the hormone.
Results
We observed that relaxin at 10 ng/ml was able to increase the level of metabolic activity of cultured neonatal rat cardiomyocytes; the rate of 2-deoxy-D-[
3
H]glucose incorporation demonstrated that relaxin also induced an increase in glucose uptake. First evidence is also offered that relaxin can activate the master energy sensor and regulator AMPK in cardiomyocytes. Moreover, the treatment of cardiomyocytes with relaxin also induced dose-dependent increases in ERK1/2, AKT, and AS160 phosphorylation. That raise in AS160 phosphorylation induced by relaxin was prevented by the pretreatment with AMPK and AKT pathways inhibitors, indicating that both molecules play important roles in the relaxin effects reported.
Conclusion
Relaxin can regulate cardiomyocyte metabolism and activate AMPK, the central sensor of energy status that maintains cellular energy homeostasis, and also ERK and AKT, two molecular sensing nodes that coordinate dynamic responses of the cell’s metabolic responses. |
doi_str_mv | 10.1007/s12020-018-1534-3 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1999200864</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1999200864</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-c1d41f0e485ad408635bc35a1527845a57ef6ca9c79612c3fa05b3ad8732a4a73</originalsourceid><addsrcrecordid>eNp1kMlKBDEQhoMo7g_gRQJevLRWZenlOIgboyii4EEINen00NrTPSbd4ry9kXEBwVNC8v1_UR9jewhHCJAdBxQgIAHME9RSJXKFbaLWRXwBWI13qXUCkD9usK0QngGEEGm2zjZEoRAlpJvs6c419F63nGxfv1HvAh9d346T0fieh3raUlO3U05tyevWekchAtNmsF1wfJj39OL4ZMHt0PSDdyW35Mu6my06u4hVO2ytoia43a9zmz2cnd6fXCRXN-eXJ6OrxMpM9InFUmEFTuWaSgV5KvXESk2oRZYrTTpzVWqpsFmRorCyItATSWWeSUGKMrnNDpe9c9-9Di70ZlYH65qGWtcNwWBRFCJ6SFVED_6gz93g45rBCECRKkCFkcIlZX0XgneVmft6Rn5hEMynerNUb6J686neyJjZ_2oeJjNX_iS-XUdALIEQv9qp87-j_2_9AOq6jZw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2012640141</pqid></control><display><type>article</type><title>Relaxin activates AMPK-AKT signaling and increases glucose uptake by cultured cardiomyocytes</title><source>Springer Nature - Complete Springer Journals</source><creator>Aragón-Herrera, A. ; Feijóo-Bandín, S. ; Rodríguez-Penas, D. ; Roselló-Lletí, E. ; Portolés, M. ; Rivera, M. ; Bigazzi, M. ; Bani, D. ; Gualillo, O. ; González-Juanatey, J. R. ; Lago, F.</creator><creatorcontrib>Aragón-Herrera, A. ; Feijóo-Bandín, S. ; Rodríguez-Penas, D. ; Roselló-Lletí, E. ; Portolés, M. ; Rivera, M. ; Bigazzi, M. ; Bani, D. ; Gualillo, O. ; González-Juanatey, J. R. ; Lago, F.</creatorcontrib><description>Purpose
Many evidences show that the hormone relaxin plays a pivotal role in the physiology and pathology of the cardiovascular system. This pleiotropic hormone exerts regulatory functions through specific receptors in cardiovascular tissues: in experimental animal models it was shown to induce coronary vasodilation, prevent cardiac damage induced by ischemia/reperfusion and revert cardiac hypertrophy and fibrosis. A tight relationship between this hormone and important metabolic pathways has been suggested, but it is at present unknown if relaxin could regulate cardiac metabolism. Our aim was to study the possible effects of relaxin on cardiomyocyte metabolism.
Methods
Neonatal rat cardiomyocytes were treated with relaxin and (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assays (MTT) were performed to assess metabolic activity; while 2-deoxy-D-[
3
H] glucose and BODIPY-labelled fatty acid incorporations were analyzed to measure glucose and fatty acid uptakes, and western blot was utilized to study the intracellular signaling pathways activated by the hormone.
Results
We observed that relaxin at 10 ng/ml was able to increase the level of metabolic activity of cultured neonatal rat cardiomyocytes; the rate of 2-deoxy-D-[
3
H]glucose incorporation demonstrated that relaxin also induced an increase in glucose uptake. First evidence is also offered that relaxin can activate the master energy sensor and regulator AMPK in cardiomyocytes. Moreover, the treatment of cardiomyocytes with relaxin also induced dose-dependent increases in ERK1/2, AKT, and AS160 phosphorylation. That raise in AS160 phosphorylation induced by relaxin was prevented by the pretreatment with AMPK and AKT pathways inhibitors, indicating that both molecules play important roles in the relaxin effects reported.
Conclusion
Relaxin can regulate cardiomyocyte metabolism and activate AMPK, the central sensor of energy status that maintains cellular energy homeostasis, and also ERK and AKT, two molecular sensing nodes that coordinate dynamic responses of the cell’s metabolic responses.</description><identifier>ISSN: 1355-008X</identifier><identifier>EISSN: 1559-0100</identifier><identifier>DOI: 10.1007/s12020-018-1534-3</identifier><identifier>PMID: 29411306</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>AKT protein ; Animal models ; Cardiomyocytes ; Cardiovascular system ; Diabetes ; Endocrinology ; Energy balance ; Fatty acids ; Fibrosis ; Glucose ; Heart ; Homeostasis ; Humanities and Social Sciences ; Hypertrophy ; Internal Medicine ; Intracellular signalling ; Ischemia ; Medicine ; Medicine & Public Health ; Metabolic pathways ; Metabolism ; multidisciplinary ; Neonates ; Original Article ; Phosphorylation ; Relaxin ; Reperfusion ; Science ; Signal transduction ; Vasodilation</subject><ispartof>Endocrine, 2018-04, Vol.60 (1), p.103-111</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2018</rights><rights>Copyright Springer Science & Business Media 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-c1d41f0e485ad408635bc35a1527845a57ef6ca9c79612c3fa05b3ad8732a4a73</citedby><cites>FETCH-LOGICAL-c372t-c1d41f0e485ad408635bc35a1527845a57ef6ca9c79612c3fa05b3ad8732a4a73</cites><orcidid>0000-0002-3739-5806</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12020-018-1534-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12020-018-1534-3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29411306$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Aragón-Herrera, A.</creatorcontrib><creatorcontrib>Feijóo-Bandín, S.</creatorcontrib><creatorcontrib>Rodríguez-Penas, D.</creatorcontrib><creatorcontrib>Roselló-Lletí, E.</creatorcontrib><creatorcontrib>Portolés, M.</creatorcontrib><creatorcontrib>Rivera, M.</creatorcontrib><creatorcontrib>Bigazzi, M.</creatorcontrib><creatorcontrib>Bani, D.</creatorcontrib><creatorcontrib>Gualillo, O.</creatorcontrib><creatorcontrib>González-Juanatey, J. R.</creatorcontrib><creatorcontrib>Lago, F.</creatorcontrib><title>Relaxin activates AMPK-AKT signaling and increases glucose uptake by cultured cardiomyocytes</title><title>Endocrine</title><addtitle>Endocrine</addtitle><addtitle>Endocrine</addtitle><description>Purpose
Many evidences show that the hormone relaxin plays a pivotal role in the physiology and pathology of the cardiovascular system. This pleiotropic hormone exerts regulatory functions through specific receptors in cardiovascular tissues: in experimental animal models it was shown to induce coronary vasodilation, prevent cardiac damage induced by ischemia/reperfusion and revert cardiac hypertrophy and fibrosis. A tight relationship between this hormone and important metabolic pathways has been suggested, but it is at present unknown if relaxin could regulate cardiac metabolism. Our aim was to study the possible effects of relaxin on cardiomyocyte metabolism.
Methods
Neonatal rat cardiomyocytes were treated with relaxin and (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assays (MTT) were performed to assess metabolic activity; while 2-deoxy-D-[
3
H] glucose and BODIPY-labelled fatty acid incorporations were analyzed to measure glucose and fatty acid uptakes, and western blot was utilized to study the intracellular signaling pathways activated by the hormone.
Results
We observed that relaxin at 10 ng/ml was able to increase the level of metabolic activity of cultured neonatal rat cardiomyocytes; the rate of 2-deoxy-D-[
3
H]glucose incorporation demonstrated that relaxin also induced an increase in glucose uptake. First evidence is also offered that relaxin can activate the master energy sensor and regulator AMPK in cardiomyocytes. Moreover, the treatment of cardiomyocytes with relaxin also induced dose-dependent increases in ERK1/2, AKT, and AS160 phosphorylation. That raise in AS160 phosphorylation induced by relaxin was prevented by the pretreatment with AMPK and AKT pathways inhibitors, indicating that both molecules play important roles in the relaxin effects reported.
Conclusion
Relaxin can regulate cardiomyocyte metabolism and activate AMPK, the central sensor of energy status that maintains cellular energy homeostasis, and also ERK and AKT, two molecular sensing nodes that coordinate dynamic responses of the cell’s metabolic responses.</description><subject>AKT protein</subject><subject>Animal models</subject><subject>Cardiomyocytes</subject><subject>Cardiovascular system</subject><subject>Diabetes</subject><subject>Endocrinology</subject><subject>Energy balance</subject><subject>Fatty acids</subject><subject>Fibrosis</subject><subject>Glucose</subject><subject>Heart</subject><subject>Homeostasis</subject><subject>Humanities and Social Sciences</subject><subject>Hypertrophy</subject><subject>Internal Medicine</subject><subject>Intracellular signalling</subject><subject>Ischemia</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolic pathways</subject><subject>Metabolism</subject><subject>multidisciplinary</subject><subject>Neonates</subject><subject>Original Article</subject><subject>Phosphorylation</subject><subject>Relaxin</subject><subject>Reperfusion</subject><subject>Science</subject><subject>Signal transduction</subject><subject>Vasodilation</subject><issn>1355-008X</issn><issn>1559-0100</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp1kMlKBDEQhoMo7g_gRQJevLRWZenlOIgboyii4EEINen00NrTPSbd4ry9kXEBwVNC8v1_UR9jewhHCJAdBxQgIAHME9RSJXKFbaLWRXwBWI13qXUCkD9usK0QngGEEGm2zjZEoRAlpJvs6c419F63nGxfv1HvAh9d346T0fieh3raUlO3U05tyevWekchAtNmsF1wfJj39OL4ZMHt0PSDdyW35Mu6my06u4hVO2ytoia43a9zmz2cnd6fXCRXN-eXJ6OrxMpM9InFUmEFTuWaSgV5KvXESk2oRZYrTTpzVWqpsFmRorCyItATSWWeSUGKMrnNDpe9c9-9Di70ZlYH65qGWtcNwWBRFCJ6SFVED_6gz93g45rBCECRKkCFkcIlZX0XgneVmft6Rn5hEMynerNUb6J686neyJjZ_2oeJjNX_iS-XUdALIEQv9qp87-j_2_9AOq6jZw</recordid><startdate>20180401</startdate><enddate>20180401</enddate><creator>Aragón-Herrera, A.</creator><creator>Feijóo-Bandín, S.</creator><creator>Rodríguez-Penas, D.</creator><creator>Roselló-Lletí, E.</creator><creator>Portolés, M.</creator><creator>Rivera, M.</creator><creator>Bigazzi, M.</creator><creator>Bani, D.</creator><creator>Gualillo, O.</creator><creator>González-Juanatey, J. R.</creator><creator>Lago, F.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3739-5806</orcidid></search><sort><creationdate>20180401</creationdate><title>Relaxin activates AMPK-AKT signaling and increases glucose uptake by cultured cardiomyocytes</title><author>Aragón-Herrera, A. ; Feijóo-Bandín, S. ; Rodríguez-Penas, D. ; Roselló-Lletí, E. ; Portolés, M. ; Rivera, M. ; Bigazzi, M. ; Bani, D. ; Gualillo, O. ; González-Juanatey, J. R. ; Lago, F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-c1d41f0e485ad408635bc35a1527845a57ef6ca9c79612c3fa05b3ad8732a4a73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>AKT protein</topic><topic>Animal models</topic><topic>Cardiomyocytes</topic><topic>Cardiovascular system</topic><topic>Diabetes</topic><topic>Endocrinology</topic><topic>Energy balance</topic><topic>Fatty acids</topic><topic>Fibrosis</topic><topic>Glucose</topic><topic>Heart</topic><topic>Homeostasis</topic><topic>Humanities and Social Sciences</topic><topic>Hypertrophy</topic><topic>Internal Medicine</topic><topic>Intracellular signalling</topic><topic>Ischemia</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolic pathways</topic><topic>Metabolism</topic><topic>multidisciplinary</topic><topic>Neonates</topic><topic>Original Article</topic><topic>Phosphorylation</topic><topic>Relaxin</topic><topic>Reperfusion</topic><topic>Science</topic><topic>Signal transduction</topic><topic>Vasodilation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aragón-Herrera, A.</creatorcontrib><creatorcontrib>Feijóo-Bandín, S.</creatorcontrib><creatorcontrib>Rodríguez-Penas, D.</creatorcontrib><creatorcontrib>Roselló-Lletí, E.</creatorcontrib><creatorcontrib>Portolés, M.</creatorcontrib><creatorcontrib>Rivera, M.</creatorcontrib><creatorcontrib>Bigazzi, M.</creatorcontrib><creatorcontrib>Bani, D.</creatorcontrib><creatorcontrib>Gualillo, O.</creatorcontrib><creatorcontrib>González-Juanatey, J. R.</creatorcontrib><creatorcontrib>Lago, F.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Endocrine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aragón-Herrera, A.</au><au>Feijóo-Bandín, S.</au><au>Rodríguez-Penas, D.</au><au>Roselló-Lletí, E.</au><au>Portolés, M.</au><au>Rivera, M.</au><au>Bigazzi, M.</au><au>Bani, D.</au><au>Gualillo, O.</au><au>González-Juanatey, J. R.</au><au>Lago, F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Relaxin activates AMPK-AKT signaling and increases glucose uptake by cultured cardiomyocytes</atitle><jtitle>Endocrine</jtitle><stitle>Endocrine</stitle><addtitle>Endocrine</addtitle><date>2018-04-01</date><risdate>2018</risdate><volume>60</volume><issue>1</issue><spage>103</spage><epage>111</epage><pages>103-111</pages><issn>1355-008X</issn><eissn>1559-0100</eissn><abstract>Purpose
Many evidences show that the hormone relaxin plays a pivotal role in the physiology and pathology of the cardiovascular system. This pleiotropic hormone exerts regulatory functions through specific receptors in cardiovascular tissues: in experimental animal models it was shown to induce coronary vasodilation, prevent cardiac damage induced by ischemia/reperfusion and revert cardiac hypertrophy and fibrosis. A tight relationship between this hormone and important metabolic pathways has been suggested, but it is at present unknown if relaxin could regulate cardiac metabolism. Our aim was to study the possible effects of relaxin on cardiomyocyte metabolism.
Methods
Neonatal rat cardiomyocytes were treated with relaxin and (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assays (MTT) were performed to assess metabolic activity; while 2-deoxy-D-[
3
H] glucose and BODIPY-labelled fatty acid incorporations were analyzed to measure glucose and fatty acid uptakes, and western blot was utilized to study the intracellular signaling pathways activated by the hormone.
Results
We observed that relaxin at 10 ng/ml was able to increase the level of metabolic activity of cultured neonatal rat cardiomyocytes; the rate of 2-deoxy-D-[
3
H]glucose incorporation demonstrated that relaxin also induced an increase in glucose uptake. First evidence is also offered that relaxin can activate the master energy sensor and regulator AMPK in cardiomyocytes. Moreover, the treatment of cardiomyocytes with relaxin also induced dose-dependent increases in ERK1/2, AKT, and AS160 phosphorylation. That raise in AS160 phosphorylation induced by relaxin was prevented by the pretreatment with AMPK and AKT pathways inhibitors, indicating that both molecules play important roles in the relaxin effects reported.
Conclusion
Relaxin can regulate cardiomyocyte metabolism and activate AMPK, the central sensor of energy status that maintains cellular energy homeostasis, and also ERK and AKT, two molecular sensing nodes that coordinate dynamic responses of the cell’s metabolic responses.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>29411306</pmid><doi>10.1007/s12020-018-1534-3</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-3739-5806</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1355-008X |
ispartof | Endocrine, 2018-04, Vol.60 (1), p.103-111 |
issn | 1355-008X 1559-0100 |
language | eng |
recordid | cdi_proquest_miscellaneous_1999200864 |
source | Springer Nature - Complete Springer Journals |
subjects | AKT protein Animal models Cardiomyocytes Cardiovascular system Diabetes Endocrinology Energy balance Fatty acids Fibrosis Glucose Heart Homeostasis Humanities and Social Sciences Hypertrophy Internal Medicine Intracellular signalling Ischemia Medicine Medicine & Public Health Metabolic pathways Metabolism multidisciplinary Neonates Original Article Phosphorylation Relaxin Reperfusion Science Signal transduction Vasodilation |
title | Relaxin activates AMPK-AKT signaling and increases glucose uptake by cultured cardiomyocytes |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T15%3A46%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Relaxin%20activates%20AMPK-AKT%20signaling%20and%20increases%20glucose%20uptake%20by%20cultured%20cardiomyocytes&rft.jtitle=Endocrine&rft.au=Arag%C3%B3n-Herrera,%20A.&rft.date=2018-04-01&rft.volume=60&rft.issue=1&rft.spage=103&rft.epage=111&rft.pages=103-111&rft.issn=1355-008X&rft.eissn=1559-0100&rft_id=info:doi/10.1007/s12020-018-1534-3&rft_dat=%3Cproquest_cross%3E1999200864%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2012640141&rft_id=info:pmid/29411306&rfr_iscdi=true |